Methyluracil with miramistin ointment 30 g. tube

Description

Methyluracil with miramistin composition
active ingredients: methyluracilum, myramistin;
1 g of ointment contains: methyluracil 50 mg, miramistin 5 mg;
excipients: propylene glycol, macrogol 400, poloxamer, cetyl alcohol, stearyl alcohol, purified water.

Dosage form
Ointment.

Pharmacological properties
This pharmaceutical preparation Methyluracil with miramistin belongs to a group of medicines used in the treatment of wound injuries and ulcers.
The drug consists of a combination of components, which together produce antimicrobial and wound healing effect.
In particular, methyluracil is able to accelerate cell regeneration, stimulate the protection of cells and tissues, produces an anti-inflammatory effect, and also has an immunostimulating effect, incl. when applied topically.
Miramistin has the ability to accelerate regenerative processes, producing an antimicrobial effect. It is active against gram-positive (staphylococci, streptococci), gram-negative (klebsiella, escherichia), aerobic and anaerobic, other bacteria, including strains resistant to antibacterial drugs.
It also produces antimycotic effect against ascomycetes and yeast-like fungi. Able to stimulate immune defense reactions when applied topically, activating regenerative processes.
It is a prophylactic agent against infection of wounds and burns, dries up the wound.

Indications
This drug Methyluracil with miramistin is used to speed up wound healing.
In particular, when treating:

• poorly healing wounds;
• radiation and trophic ulcers (including in patients with diabetic angiopathy, ulcers in weakened patients with suppressed immunity);
• burns and other skin damage.

The drug has a photoprotective effect in patients with photodermatosis.

Contraindications
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
Also contraindicated for:

• acute and chronic forms of leukemia;
• lymphogranulomatosis;
• malignant diseases of the bone marrow.

Children
It is not used in pediatric practice.

Application during pregnancy and lactation
This drug should not be used in the treatment of pregnant women, since there is no clinical experience and it is not known how dangerous its use is, both for the woman and the fetus.
If it is necessary to take the drug during breastfeeding, it is advisable to interrupt lactation.

Method of administration and dosage
Methyluracil with miramistin is applied topically to the affected surface.
After the standard procedure for treating wounds and burns has been carried out, the ointment is applied directly to the affected surface.
Then a sterile gauze bandage is applied to the wound or an ointment is applied to the dressing, and then to the wound.
It is also permissible to use tampons impregnated with the drug, carefully filling the cavities of purulent wounds after their surgical treatment, or gauze turundas with ointment, introducing them into the fistular passages.
The drug is used once every 1 or 2 days. The dose depends on the area of ​​the wound surface and the degree of purulent exudation.
The duration of treatment is due to the dynamics of cleansing and healing wounds. Treatment with the drug stops when wound granulations appear and the wounds are cleared of wound exudate.

Overdose
Overdose has not been observed at the moment. Theoretically, with prolonged use on large surfaces of the skin, it is likely that the active substances of the drug will enter the systemic circulation, in volumes that can cause intoxication.
In this case, symptoms such as:

• headache, dizziness;
• hypersensitivity reactions.

Miramistin acts as a cationic detergent and may prolong bleeding time.
In case of accidental overdose, you should reduce the amount of the applied drug or discontinue its use.

Side effects
The drug is usually well tolerated.
In some cases, hypersensitivity reactions are possible, such as:

• hyperemia, itching, burning;
• rash, hives, dry skin;
• allergic dermatitis, other forms of skin irritation.

If side effects appear, the use of the drug should be suspended or the dose used should be reduced.

Storage conditions and periods
The shelf life is up to 2 years.
Storage temperature should not exceed 25 ° C.